Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Date
2015
Author
Sevinc, Alper
Guler, Nilufer
Onur, Handan
Uslu, Ruchan
Altinbas, Mustafa
İÇLİ, FİKRİ
Altundag, Kadri
AKBULUT, HAKAN
PAYDAŞ, SEMRA
Basaran, Gul
Dogu, Gamze G.
Isikdogan, Abdurrahman
GÖKMEN, ERHAN
UYGUN, KAZIM
Ustuner, Zeki
YAREN, ARZU
Demirkan, Binnaz
Ata, Alper
ÖZKAN, METİN
Arican, Ali
Saip, Pinar
Mandel, Nil M.
Erlap, Yesim
Coskun, Ugur
Sezgin, Canfeza
Metadata
Show full item record
Abstract
Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.
URI
http://hdl.handle.net/20.500.12627/108915
https://doi.org/10.1007/s12282-013-0506-y
Collections